AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions 1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA ...

Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news begins with adjusted earnings per share of $2.16 easily beating Wall Street ...

For the year, AbbVie’s revenue reached $56.3 billion, a 3.7% increase from 2023 and a turnaround from the 6.4% decrease the company saw when it reported annual results a year ago. AbbVie ...

Get Wall Street's Hottest Chart Every Morning AbbVie Inc. ABBV shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share of $2.16, beating the street ...